RxDoctor Payments Data

Harcharan Bains, MD

Psychiatry · Bolivar, MONPI 1295802403

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 22 payments — averaging $94.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$2K
  • Alkermes, Inc.$119
  • Sunovion Pharmaceuticals Inc.$80
  • Johnson & Johnson$72
  • Otsuka America Pharmaceutical, Inc.$30
  • AbbVie$29
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$40820%
  • Education$543%
  • Other$1,62578%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 75th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$18,271
Medicare patients
16
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$145,788
Invega TrinzaPaliperidone Palmitate14$109,424
AustedoDeutetrabenazine15$64,594
Abilify MaintenaAripiprazole14$38,541
FanaptIloperidone16$28,792
RexultiBrexpiprazole20$27,142
BelsomraSuvorexant44$20,280
VraylarCariprazine Hcl12$17,730
Aripiprazole246$16,748
TrintellixVortioxetine Hydrobromide31$15,241
Fluvoxamine Maleate136$9,180
Atomoxetine Hcl38$7,007
Olanzapine OdtOlanzapine29$5,726
Venlafaxine Hcl ErVenlafaxine Hcl181$4,495
Olanzapine190$3,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$72$255,21254 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$30$65,68334 claims
AbbVieVraylar$29$17,73012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$15,24131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Bolivar

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →